This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2). It is delivered intraperitoneally (IP) to patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
5 Primary · 12 Secondary · Reporting Duration: 1 year (Part 1); 1 year (Part 2)
Experimental Treatment
44 Total Participants · 2 Treatment Groups
Primary Treatment: Part 1 escalating ABV-001 between 0.6 and 3.6 ug hIL-2/kg/day; and Part 2 ABV-001 at the MTD/RP2D · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: